

Spyros E. Zographos

Research Director
Institute of Chemical Biology

Phone: +30-2107273850

E-mail: sez@icie.gr

Website: [Structural Biology and Chemistry](#)



Scopus[®]

Clarivate™

CV (Last updated January 2026)



Spyros E. Zographos is principal investigator of the Structural Biology and Chemistry Group at the Institute of Chemical Biology (ICB). He is a chemist with vast experience in molecular biology, biochemistry and structural biology. He earned his Bachelor's (1992) and Ph.D. degree from the Department of Chemistry at the University of Athens, Greece, in 1992 and 2000, respectively. He served as a visiting lecturer in the Department of Chemistry at the University of Cyprus (UCY) (2000-2001) and afterwards as a Marie Curie postdoctoral research fellow in the Department of Biological Sciences, UCY (2001-2004). He was awarded a Marie Curie reintegration grant and in 2004 joined Institute of Biology, Medicinal Chemistry and Biotechnology (IBMCB) as a postdoctoral research fellow. He became an Assistant researcher in 2006, a senior researcher in 2010 and Research Director in 2018.

Summary of Scientific Achievements

His scientific achievements are presented in 71 peer-reviewed original research articles, 3 peer-reviewed reviews, 4 chapters in books, 1 EL/EU patent, 81 oral/poster presentations in conferences and 28 short communications. He has deposited as structure author 120 protein structures at the Protein Data Bank.

WoS/Scopus: h-index 31, Total times cited 2.702, without self-citations: 2.455.

Google Scholar: i10-index: 62, Times Cited: total 3,720.

Dr. Spyros Zographos has significant teaching experience. As a visiting lecturer at the Chemistry Department of University of Cyprus, he taught Medicinal Chemistry, Biochemistry, X-ray Protein Crystallography to undergraduate students and also Enzymology-Structural Biology as part of a postgraduate course. He also taught Enzymology at the MSc Program in Food Science and Technology of the Technological Educational Institute of Athens. Currently he is teaching Enzymology at the joint MSc program "Bioentrepreneurship" (University of Thessaly - NHRF) and Structural Biology at the joint MSc program "Biotechnology" (National and Kapodistrian university of Athens – NHRF). He is supervising /has supervised 8 Post-doctoral researchers, 4 PhD and 21 MSc Theses, 9 final year research projects and 3 Internships.

His research activities have been supported by 10 EU grants (2 as coordinator), 12 national grants from GSRT, NSRF-EPANAK, Hellenic Foundation for Research and

Innovation (H.F.R.I.), State Scholarships Foundation (IKY) (4 as coordinator) and 3 research grants from Cyprus RPF (1 as coordinator) as well as by 2 collaborative projects with Sanofi-Aventis Pharma and Pfizer Inc., USA. He has received 42 EU travel/access grants for X-ray crystallographic data collection (more than 500 shifts) and HT-protein expression at EU large scale facilities/laboratories.

He was elected Board member (2010-2014) and President (2014-2020) of the Hellenic Crystallographic Association (HeCrA). Currently, he serves as President of the Scientific Council of ICB (ΕΣΙ), Deputy Director and member of the Coordination Committee of the MSc program "Bioentrepreneurship" and member of the Gender Equality and Anti-Discrimination Committee of NHRF.

Research interests

The general theme that underlies the work of Dr. Zographos' research team is the functional and structural characterization of proteins of pharmaceutical and biotechnological interest. His team employs recombinant DNA technology, protein expression systems, and advanced purification strategies to produce high-quality protein targets. These proteins are investigated using X-ray crystallography, bioNMR, and cryo-EM, in combination with *in silico* template-based modeling and AI approaches, as well as *in vitro* biochemical and biophysical binding assays and enzyme kinetics. Together, these complementary methodologies provide deep insight into structure–function relationships and regulatory mechanisms of protein targets. Such knowledge guides computational and synthetic chemists in the rational design, synthesis, and discovery of novel therapeutic agents and other products of biotechnological relevance.

Over the past two decades, the group has investigated protein targets implicated in diverse biological processes and diseases, including type 2 diabetes mellitus (glycogen phosphorylase and glucokinase); cancer (human coilin-interacting nuclear ATPase, hCINAP, and BRAF(V600E)); inflammation (ligand-binding domain of the glucocorticoid receptor, GR-LBD); aging (human proteasome); melanogenesis and enzymatic browning in foods and beverages (tyrosinase); and insect chemoreception (odorant-binding proteins and chemosensory proteins, OBPs/CSPs, from mosquitoes, oriental fruit flies, and silkworms, as well as the mosquito odorant receptor co-receptor ORco).

Structure-assisted inhibitor design studies have led to the discovery of more than 100 inhibitors of **glycogen phosphorylase (GP)**, a key target for type 2 diabetes mellitus, including novel synthetic inhibitor classes and natural products such as flavonoids and terpenes.

Since 2010, Dr. Zographos' research has focused on insect olfaction, with the goal of applying structure-based approaches to discover new and effective agents aimed at reducing the spread of insect-transmitted infectious diseases and controlling insects of agricultural importance. The research program emphasizes the biochemical, molecular, functional, and structural characterization of mosquito and pest insect **odorant-binding proteins (OBPs)**, **chemosensory proteins (CSPs, SAPs)**, and the mosquito **seven-transmembrane odorant receptor co-receptor (ORco)**. These proteins play crucial roles in host-seeking behavior by detecting organic compounds released by humans, animals, and plants. The group has developed and validated OBP- and ORco-guided, structure-aided discovery protocols, enabling the identification of

novel bioactive molecules that induce repellency or anosmia, as well as a patented repellent formulation based on OBP-guided selection of essential oils ([EP4321023A1](#)).

More recently, the laboratory has expanded its research toward **OBP-based photonic biosensors**, in collaboration with the NHRF/TCPI Institute, with applications spanning health, environmental monitoring, forensics, border security, and related fields (Funding: Exploratory Interdisciplinary Projects of Early-Career Researchers, 1st Internal Call, 2025–2026).

Education and qualifications

2000: PhD in Chemistry, National and Kapodistrian University of Athens

1996: X-ray protein crystallography trainee, University of Oxford, U.K.

1994: X-ray protein crystallography trainee, University of Oxford, U.K.

1993: X-ray protein crystallography trainee, University of Oxford, U.K.

1992: BSc in Chemistry, National and Kapodistrian University of Athens

Fellowships

2005-2007: Marie Curie Reintegration Fellowship by the European Union (24 months)

2001-2004: Marie Curie Postdoctoral Fellowship by the European Union (36 months)

1992-1997: Doctoral studentship from the National Hellenic Research Foundation (48 months)

Appointments

Jul 2018 - present: Research Director, ICB, NHRF

Mar 2010 - Jul 2018: Senior Researcher, IBMCB, NHRF

Mar 2006 - Feb 2009: Research Assistant, IOPC, NHRF

Sep 2004 - Feb 2006: Marie Curie Postdoctoral Fellow, IOPC, NHRF

Aug 2001 - Aug 2004: Marie Curie Postdoctoral Fellow, Dept. of Biol. Sciences, UCY

Sep 2000 - Jun 2001: Visiting Lecturer, Dept. of Chemistry, UCY

Feb 2000 - Aug 2000: Postdoctoral Fellow, IBRB, NHRF

Jan 1998 - Dec 2000: Second Lieutenant, Supply and Transp. Corps, Hellenic Army

Committee memberships

2025-present: Member of the Gender Equality and Anti-Discrimination Committee of NHRF

2022-present: President of the Scientific Advisory Board of Institute of Chemical Biology, NHRF.

2014-present: Deputy Director & Member of the Coordination committee of MSc program "Bioentrepreneurship"

2008-present: Permanent board member of the "Nikos Oikonomakos award" for structural biology

2008-present: Co-organizer for 23 conferences/workshops (7 as president of the organizing committee)

- 2014-2022: Elected member of the Scientific Advisory Board of Institute of Chemical Biology, NHRF.
- 2014-2020: President of the Hellenic Crystallographic Association
- 2010-2014: Elected board member (treasurer) of the Hellenic Crystallographic Association
- 2001-2002: Biology panel member (question selection committee) of the 2001 and 2002 pancyprian examinations for the admission of graduate secondary students to the Universities of Cyprus and Greece.
- 2001: Final year projects qualifying examination committee, Dept. of Chemistry, UCY

Publications in refereed journal

1. Feng M[§], Fei SG[§], Papakyriakou A, Christodoulou E, Lai WX, Luo WJ, Xia JM, Huang YG, **Zographos SE***, Swevers L*, Sun JC* (2025). Chemosensory protein 3 is a brain host factor for the induction of enhanced-locomotory activity in the BmNPV-silkworm infection model. *Plos Pathogens* 21(12): e1013701 → [Journal](#) | [PubMed](#)

[§] These authors contributed equally to this work

*JIF*²⁰²⁴: 4.9

2. Chazapi E, Kritsi E, Potamitis C, Liggri PGV, **Tsitsanou KE**, Drakou CE, Michaelakis A, Papachristos DP, **Zographos SE***, Zervou M* & Calogeropoulou T* (2025). AgamOBP1-Directed Discovery of Repellents to Control the Spread of Mosquito-Borne Diseases. *ChemMedChem*, 20(21):e202500555 → [Journal](#) | [PubMed](#)

*JIF*²⁰²⁴: 3.4

3. Thanu VC, Jabeen A, **Zographos SE**, Taylor PW, Ranganathan S* (2025). TBM preferred to AlphaFold 3 for functional models of insect odorant receptors. *Comput. Struct. Biotechnol. J.* 27, 3908-3918 → [Journal](#) | [PubMed](#)

*JIF*²⁰²⁴: 4.1

4. Kythreoti, G.[§], Thireou, T.[§], Karoussiotis, C., Georgoussi, Z., Liggri, P.G.V., Papachristos, D.P., Michaelakis, A., Karras, V., **Zographos, S.E.***, Schulz, S., Iatrou, K.* (2024). Natural volatiles preventing mosquito biting: An integrated screening platform for accelerated discovery of ORco antagonists. *J Biol Chem* 300, 107939 → [Journal](#) | [PubMed](#)

[§] These authors contributed equally to this work

*JIF*²⁰²⁴ : 3.9

5. Mam B[§], Tsitsanou KE[§], Liggri PGV, Saitta F, Stamati ECV, Mahita J, Leonis G, Drakou CE, Papadopoulos M, Arnaud P, Offmann B, Fessas D, Sowdhamini R, **Zographos SE***. (2023) Influence of pH on indole-dependent heterodimeric interactions between Anopheles gambiae odorant-binding proteins OBP1 and OBP4. *Int J Biol Macromol* 245, 125422 → [Journal](#) | [PubMed](#)

[§] These authors contributed equally to this work

*JIF*²⁰²³ : **7.7**PDBs: [8C6E](#), [8C6G](#), [8BXV](#)

6. Liggri PGV, Pérez-Garrido A, Tsitsanou KE, Dileep KV, Michaelakis A, Papachristos DP, Pérez-Sánchez H, **Zographos SE***. (2023) 2D finger-printing and molecular docking studies identified potent mosquito repellents targeting odorant binding protein 1. *Insect Biochem Mol Biol* 157, 103961 → [Journal](#) | [PubMed](#)

*JIF*²⁰²² : **3.8**

7. Liggri PGV, Tsitsanou KE, Stamati ECV, Saitta F, Drakou CE, Leonidas DD, Fessas D, **Zographos SE***. (2023) The structure of AgamOBP5 in complex with the natural insect repellents Carvacrol and Thymol: Crystallographic, fluorescence and thermodynamic binding studies. *Int J Biol Macromol* 237, 124009 → [Journal](#) | [PubMed](#)

*JIF*²⁰²² : **7.7**PDBs: [8BXU](#), [8BXW](#), [8BXV](#)

8. Kritsi E[§], Liggri PGV[§], Stamati ECV, Tsitsanou KE, **Zographos SE***, Michaelakis A, Papachristos D, Zoumpoulakis P. (2022) A Combined Computational Methodology for the Discovery of Hit Compounds with Putative Insect Repellency Properties. *ChemMedChem* 17(16):e202200271 → [Journal](#) | [PubMed](#)

[§] These authors contributed equally to this work*JIF*²⁰²² : **3.4**

9. Chatzidaki, MD, Demisli, S, Zingkou, E, Liggri, PGV, Papachristos, DP, Balatsos, G, Karras, V, Nallet, F. Michaelakis, A, Sotiropoulou, G, **Zographos, SE**, Papadimitriou, V. (2022) Essential oil-in-water microemulsions for topical application: structural study, cytotoxic effect and insect repelling activity. *Colloids Surf. A Physicochem. Eng. Asp.* 654, 130159 → [Journal](#)

*JIF*²⁰²² : **5.2**

10. Fytrou A, Papachristos, DP, Milonas, PG, Giatropoulos, A, **Zographos, SE**, and Michaelakis, A. (2022) Behavioural response of *Culex pipiens* biotype *molestus* to oviposition pheromone. *Journal of Insect Physiology* 138, 104383 → [Journal](#) | [PubMed](#)

*JIF*²⁰²² : **2.2**

11. Leonidas DD*, **Zographos SE***, Tsitsanou KE, Skamnaki VT, Stravodimos G, Kyriakis E (2021) Glycogen phosphorylase revisited: extending the resolution of the R- and T-state structures of the free enzyme and in complex with allosteric activators. *Acta Crystallogr F* 77, 303-311 → [Journal](#) | [PubMed](#)

*JIF*²⁰²¹ : **1.056**PDBs: [3E3L](#), [3E3N](#), [3E3O](#), [7P7D](#)

12. Kyriakis E, Karra AG, Papaioannou O, Solovou T, Skamnaki VT, Liggri PGV, **Zographos SE**, Szennyes E, Bokor E, Kun S, Psarra AG, Somsak L, Leonidas DD (2020) The architecture of hydrogen and sulfur sigma-hole interactions explain differences in the inhibitory potency of

C-beta-d-glucopyranosyl thiazoles, imidazoles and an N-beta-d glucopyranosyl tetrazole for human liver glycogen phosphorylase and offer new insights to structure-based design. *Bioorg Med Chem.* 28, 115196 → [Journal](#) | [PubMed](#)

JIF²⁰²⁰: **3.409**

PDBs: [6S4H](#), [6S4K](#), [6S4O](#), [6S4P](#), [6S4R](#), [6S51](#), [6S52](#)

13. Szabo, KE, Kyriakis, E, Psarra, AG, Karra, AG, Sipos, A, Docsa, T, Stravodimos, GA, Katsidou, E, Skamnaki, VT, Liggri, PGV, **Zographos, SE**, Mandi, A, Kiraly, SB, Kurtan, T, Leonidas, DD, and Somsak, L (2019) Glucopyranosylidene-spiro-imidazolinones, a New Ring System: Synthesis and Evaluation as Glycogen Phosphorylase Inhibitors by Enzyme Kinetics and X-ray Crystallography. *J Med Chem.* 62, 6116-6136 → [Journal](#) | [PubMed](#)

JIF²⁰¹⁹: **6.336**

PDBs: [6QA6](#), [6QA7](#), [6QA8](#)

14. Fischer T, Koulas SM, Tsagkarakou AS, Kyriakis E, Stravodimos GA, Skamnaki VT, Liggri PGV, **Zographos SE**, Riedl R, Leonidas DD (2019) High Consistency of Structure-Based Design and X-Ray Crystallography: Design, Synthesis, Kinetic Evaluation and Crystallographic Binding Mode Determination of Biphenyl-N-acyl-β-d-Glucopyranosylamines as Glycogen Phosphorylase Inhibitors. *Molecules* 24, 1322+ → [Journal](#) | [PubMed](#)

JIF²⁰¹⁹: **3.309**

PDBs: [6R0H](#), [6R0I](#)

15. Thireou T, Kythreoti G, Tsitsanou KE, Koussis K, Drakou CE, Kinnersley J, Krober T, Guerin PM, Zhou, J-J, Iatrou K, Eliopoulos E, **Zographos SE*** (2018). Identification of novel bioinspired synthetic mosquito repellents by combined ligand-based screening and OBP-structure-based molecular docking. *Insect Biochem Mol Biol.* 98, 48–61 → [Journal](#) | [PubMed](#)

JIF²⁰¹⁸: **3.737**

16. Bokor E, Kyriakis E, Solovou TG, Koppany C, Kantsadi AL, Szabo KE, Szakacs A, Stravodimos GA, Docsa T, Skamnaki VT, **Zographos SE**, Gergely P, Leonidas DD, Somsak L (2017) Nanomolar inhibitors of glycogen phosphorylase based on beta-D-glucosaminyl heterocycles: a combined synthetic, enzyme kinetic and protein crystallography study. *J Med Chem.* 60, 9251–9262 → [Journal](#) | [PubMed](#)

JIF²⁰¹⁷: **6.590**

PDBs: [5050](#), [5052](#), [5054](#), [5056](#)

17. Drakou CE, Tsitsanou KE, Potamitis C, Fessas D, Zervou M, **Zographos SE*** (2017) The crystal structure of the AgamOBP1*Icaridin complex reveals alternative binding modes and stereo-selective repellent recognition. *Cell Mol Life Sci.* 74, 319–338 → [Journal](#) | [PubMed](#)

JIF²⁰¹⁷: **6.998**

PDBs: [5EL2](#)

18. Peppas VI, Venkat H, Kantsadi AL, Inamdar SR, Bhat GG, Eligar S, Shivanand A, Chachadi VB, Satisha GJ, Swamy BM, Skamnaki VT, **Zographos SE**, Leonidas DD (2015) Molecular Cloning,

Carbohydrate Specificity and the Crystal Structure of Two Sclerotium rolfsii Lectin Variants.
Molecules 20, 10848-65 → [Journal](#) | [PubMed](#)

*JIF*²⁰¹⁵: **2.465**

PDBs: [4YLD](#), [4Z2F](#), [4Z2Q](#), [4Z2S](#)

- 19 Parmenopoulou V, Kantsadi AL, Tsirkone VG, Chatzileontiadou DS, Manta S, **Zographos SE**, Molfeta C, Archontis G, Agius L, Hayes JM, Leonidas DD, Komiotis D. (2014) "Structure based inhibitor design targeting glycogen phosphorylase b. Virtual screening, synthesis, biochemical and biological assessment of novel N-acyl- β -d-glucopyranosylamines" *Bioorg Med Chem.* 22, 4810-25 → [Journal](#) | [PubMed](#)

*JIF*²⁰¹⁴: **2.793**

PDBs: [4MHO](#), [4MHS](#), [4MIC](#), [4MI3](#), [4MI6](#), [4MI9](#)

- 20 Czifrák K, Páhi A, Deák S, Kiss-Szikszai A, Kövér KE, Docsa T, Gergely P, Alexacou KM, Papakonstantinou M, Leonidas DD, **Zographos SE**, Chrysina ED, Somsák L. (2014) "Glucopyranosylidene-spiro-iminothiazolidinone, a new bicyclic ring system: synthesis, derivatization, and evaluation for inhibition of glycogen phosphorylase by enzyme kinetic and crystallographic methods" *Bioorg Med Chem.* 22, 4028-41 → [Journal](#) | [PubMed](#)

*JIF*²⁰¹⁴: **2.793**

PDBs: [4CTM](#), [4CTN](#), [4CTO](#)

21. Tsitsanou KE, Drakou CE, Thireou T, Gruber AV, Kythreoti G, Azem A, Fessas D, Eliopoulos E, Iatrou K, **Zographos SE*** (2013) "The crystal and solution studies of the "Plus-C" odorant binding protein 48 from *Anopheles gambiae*: Control of binding specificity through 3D domain-swapping" *J Biol Chem* 288, 33427-38 → [Journal](#) | [PubMed](#)

*JIF*²⁰¹³: **4.600**

PDBs: [4IJ7](#), [4KYN](#)

22. Skamnaki VT, Peumans WJ, Kantsadi AL, Cubeta MA, Plas K, Pakala S, **Zographos SE**, Smagghe G, Nierman WC, Van Damme EJ, Leonidas DD. (2013) "Structural analysis of the *Rhizoctonia solani* agglutinin reveals a domain swapping dimeric assembly" *FEBS J.* 280, 1750-1763 → [Journal](#) | [PubMed](#)

*JIF*²⁰¹³: **3.986**

PDBs: [4G9M](#), [4G9N](#)

23. Tsitsanou KE, Hayes JM, Keramioti M, Mamais M, Oikonomakos NG, Kato A, Leonidas DD, **Zographos SE*** (2013) "Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: Comparison of chrysin and flavopiridol." *Food Chem Toxicol* 61, 14-27 → [Journal](#) | [PubMed](#)

*JIF*²⁰¹³: **2.610**

PDBs: [3EBO](#), [3EBP](#)

24. Parmenopoulou V, Chatzileontiadou DS, Manta S, Bougiatioti S, Maragozidis P, Gkaragkouni DN, Kaffesaki E, Kantsadi AL, Skamnaki VT, **Zographos SE**, Zounpoulakis P, Balatsos NA,

Komiotis D, Leonidas DD (2012) "Triazole pyrimidine nucleosides as inhibitors of Ribonuclease A. Synthesis, biochemical, and structural evaluation." *Bioorg Med Chem.* **20**, 7184-7193. → [Journal](#) | [PubMed](#)

*JIF*²⁰¹²: **2.903**

PDBs: [4G90](#), [4G8V](#), [4G8Y](#)

25. A.L. Kantsadi, S. Manta, A.-M.G. Psarra, A. Dimopoulou, C. Kiritsis, V. Parmenopoulou, V.T. Skamnaki, P. Zoumpoulakis, **S.E. Zographos**, D.D. Leonidas, and D. Komiotis (2012) "The binding of C5-alkynyl and alkylfurano[2,3-d]pyrimidine glucopyranonucleosides to glycogen phosphorylase b. Synthesis, biochemical and biological assessment." *European Journal of Medicinal Chemistry* **54**, 740-749. → [Journal](#) | [PubMed](#)

*JIF*²⁰¹²: **3.499**

PDBs: [4EJ2](#), [4EKE](#), [4EL5](#), [4EKY](#), [4ELO](#)

26. Nagy V, Felföldi N, Kónya B, Praly JP, Docsa T, Gergely P, Chrysina ED, Tiraidis C, Kosmopoulou MN, Alexacou KM, Konstantakaki M, Leonidas DD, **Zographos SE**, Oikonomakos NG, Kozmon S, Tvaroška I, Somsák L (2012) "N-(4-Substituted-benzoyl)-N'-(β-d-glucopyranosyl)ureas as inhibitors of glycogen phosphorylase: Synthesis and evaluation by kinetic, crystallographic, and molecular modelling methods" *Bioorg Med Chem.* **20**, 1801-1816. → [Journal](#) | [PubMed](#)

*JIF*²⁰¹²: **2.903**

PDBs: [2QNB](#), [2QLM](#), [2QLN](#), [2QN3](#), [2QN7](#), [2QN8](#), [2QN9](#)

27. Manta S, Xipnitou A, Kiritsis C, Kantsadi AL, Hayes JM, Skamnaki VT, Lamprakis C, Kontou M, Zoumpoulakis P, **Zographos SE**, Leonidas DD, Komiotis D. (2012) "3'-axial CH₂ OH substitution on glucopyranose does not increase glycogen phosphorylase inhibitory potency. QM/MM-PBSA calculations suggest why." *Chem Biol Drug Des.* **79**, 663-673. → [Journal](#) | [PubMed](#)

*JIF*²⁰¹²: **2.469**

PDBs: [3SYM](#), [3SYR](#)

28. Kantsadi AL, Hayes JM, Manta S, Skamnaki VT, Kiritsis C, Psarra AM, Koutsogiannis Z, Dimopoulou A, Theofanous S, Nikoleousakos N, Zoumpoulakis P, Kontou M, Papadopoulos G, **Zographos SE**, Komiotis D, Leonidas DD. (2012) "The σ-hole phenomenon of halogen atoms forms the structural basis of the strong inhibitory potency of C5 halogen substituted glucopyranosyl nucleosides towards glycogen phosphorylase b" *ChemMedChem.* **7**, 722-732. → [Journal](#) | [PubMed](#)

*JIF*²⁰¹²: **2.835**

PDBs: [3T3D](#), [3T3E](#), [3T3G](#), [3T3H](#), [3T3I](#)

29. Christina E. Drakou, Anna Malekkou, Joseph M. Hayes, Carsten W. Lederer, Demetres D. Leonidas, Nikos G. Oikonomakos, Angus I. Lamond, Niovi Santama, and **Zographos SE*** (2012) "hCINAP is an atypical mammalian nuclear adenylate kinase with an ATPase motif: Structural and functional studies" *Proteins* **80**, 206-220. → [Journal](#) | [PubMed](#)

*JIF*²⁰¹²: **3.337**

PDBs: [3IIJ](#), [3IIK](#), [3IIL](#), [3IIM](#)

30. Tsitsanou KE, Thireou T, Drakou CE, Koussis K, Keramioti MV, Leonidas DD, Eliopoulos E, Iatrou K, **Zographos SE*** (2012) "Anopheles gambiae odorant binding protein crystal complex with the synthetic repellent DEET: implications for structure-based design of novel mosquito repellents" *Cellular Molecular Life Sci.* **69**, 283-297. → [Journal](#) | [PubMed](#)

*JIF*²⁰¹²: **5.615**

PDB: [3N7H](#)

31. Alexacou KM, Zhang YZ, Praly JP, **Zographos SE**, Chrysina ED, Oikonomakos NG, Leonidas DD (2011) "Halogen-substituted (C- β -d-glucopyranosyl)-hydroquinone regioisomers: Synthesis, enzymatic evaluation and their binding to glycogen phosphorylase" *Bioorgan Med Chem* **19**, 5125-5136. → [Journal](#) | [PubMed](#)

*JIF*²⁰¹¹: **2.921.**

PDBs: [3NP7](#), [3NP9](#), [3NPA](#), [3S0J](#)

32. J.M. Hayes, V.T. Skamnaki, G. Archontis, C. Lamprakis, J. Sarrou, N. Bischler, A-L. Skaltsounis, **S.E. Zographos**, N.G. Oikonomakos (2011) "Kinetics, in silico docking, molecular dynamics and MM-GBSA binding studies on prototype indirubins, KT5720 and staurosporine as phosphorylase kinase ATP-binding site inhibitors: The role of water molecules examined" *Proteins* **79**, 703-719. → [Journal](#) | [PubMed](#)

Cover Story



*JIF*²⁰¹¹: **3.392**

33. V.G. Tsirkone, E. Tsoukala, C. Lamprakis, S. Manta, J.M. Hayes, V.T. Skamnaki, C. Drakou, **S.E. Zographos**, D. Komiotis, D.D. Leonidas (2010) "1-(3-Deoxy-3-fluoro-beta-D-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies" *Bioorgan Med Chem* **18**, 3413-3425. → [Journal](#) | [PubMed](#)

*JIF*²⁰¹⁰: **2.978.**

PDBs: [3L79](#), [3L7A](#), [3L7B](#), [3L7C](#), [3L7D](#)

34. K.M. Alexacou, A.C. Tenchiu Deleanu, E.D. Chrysina, M.D. Charavgi, I.D. Kostas, **S.E. Zographos**, N.G. Oikonomakos, D.D. Leonidas (2010) "The binding of β -D-glucopyranosyl-thiosemicarbazone derivatives to glycogen phosphorylase: A new class of inhibitors" *Bioorgan Med Chem* **18**, 7911-7922. → [Journal](#) | [PubMed](#)

*JIF*²⁰¹⁰: **2.978.**

PDBs: [3MQF](#), [3MTA](#), [3MTZ](#), [3MS7](#), [3MTB](#), [3MT8](#), [3MS4](#), [3MSC](#), [3MT9](#), [3NC4](#), [3MRV](#), [3MTD](#), [3MRX](#), [3MS2](#), [3MRT](#)

35. Dossi K, Tsirkone VG, Hayes JM, Matousek J, Pouckova P, Soucek J, Zadinova M, **Zographos SE**, & Leonidas DD (2009) "Mapping the ribonucleolytic active site of bovine seminal ribonuclease. The binding of pyrimidinyl phosphonucleotide inhibitors" *Eur J Med Chem* **44**, 4496-4508.

→ [Journal](#) | [PubMed](#)

*JIF*²⁰⁰⁹: **3.269**

PDBs: [3DJQ](#), [3DJP](#), [3DJQ](#), [3DJV](#), [3DJX](#)


36. Benltifa M, Hayes JM, Vidal S, Gueyrard D, Goekjian PG, Praly J-P, Kizilis G, Tiraidis C, Alexacou K-M, Chrysina ED, **Zographos SE**, Leonidas DD, Archontis G & Oikonomakos NG (2009) "Glucose-based Spiro-isoxazolines: A New Family of Potent Glycogen Phosphorylase Inhibitors" *Bioorgan Med Chem* **17**, 7368-7380. → [Journal](#) | [PubMed](#)

*JIF*²⁰⁰⁹: **2.822**

PDBs: [2QRG](#), [2QRH](#), [2QRM](#), [2QRP](#), [2QRQ](#)

37. Tsirkone VG, Dossi K, Drakou C, **Zographos SE**, Kontou M & Leonidas DD (2009) "Inhibitor design for ribonuclease A: the binding of two 5'-phosphate uridine analogues" *Acta Crystallogr F* **65**, 671-677. → [Journal](#) | [PubMed](#)

Cover Story



*JIF*²⁰⁰⁹: **0.551**

PDBs: [3DXG](#), [3DXH](#)

38. Chrysina ED, Bokor E, Alexacou KM, Charavgi MD, Oikonomakos GN, **Zographos SE**, Leonidas DD, Oikonomakos NG & Laszlo S (2009) "Amide-1,2,3-triazole bioisosterism: the glycogen phosphorylase case" *Tetrahedron-Asymmetry* **20**, 733-740. → [Journal](#)

*JIF*²⁰⁰⁹: **2.625**

PDBs: [3G2H](#), [3G2L](#), [3G2K](#), [3G2I](#), [3G2N](#), [3G2J](#)

39. Samanta A, Leonidas DD, Dasgupta S, Pathak T, **Zographos SE** & Oikonomakos NG (2009) "Morpholino, Piperidino, and Pyrrolidino Derivatives of Pyrimidine Nucleosides as Inhibitors of Ribonuclease A: Synthesis, Biochemical, and Crystallographic Evaluation" *J Med Chem* **52**, 932-942. → [Journal](#) | [PubMed](#)

*JIF*²⁰⁰⁹: **4.802**

PDBs: [3D6O](#), [3D6P](#), [3D6Q](#), [3D7B](#), [3D8Y](#), [3D8Z](#)

40. Wen XA, Sun HB, Liu J, Cheng KG, Zhang P, Zhang LY, Hao J, Ni PZ, **Zographos SE**, Leonidas DD, Alexacou KM, Gimisis T, Hayes JM & Oikonomakos NG (2008) "Naturally occurring

pentacyclic triterpenes as inhibitors of glycogen phosphorylase: Synthesis, structure-activity relationships, and X-ray crystallographic studies" *J Med Chem* **51**, 3540-3554. → [Journal](#) | [PubMed](#)

*JIF*²⁰⁰⁸: **4.898**

PDBs: [2QN1](#), [2QN2](#)

41. Alexacou KM, Hayes JM, Tiraidis C, **Zographos SE**, Leonidas DD, Chrysina ED, Archontis G, Oikonomakos NG, Paul JV, Varghese B & Loganathan D (2008) "Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: Comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding" *Proteins* **71**, 1307-1323. → [Journal](#) | [PubMed](#)

*JIF*²⁰⁰⁸: **3.419**

PDBs: [2PYD](#), [2PYI](#)

42. Tiraidis C, Alexacou KM, **Zographos SE**, Leonidas DD, Gimisis T & Oikonomakos NG (2007) "FR258900, a potential anti-hyperglycemic drug, binds at the allosteric site of glycogen phosphorylase" *Protein Sci* **16**, 1773-1782. → [Journal](#) | [PubMed](#)

*JIF*²⁰⁰⁷: **3.135**

PDB: [2OFF](#)

43. Pantelidou M, **Zographos SE**, Lederer CW, Kyriakides T, Pfaffl MW & Santama N (2007) "Differential expression of molecular motors in the motor cortex of sporadic ALS" *Neurobiol Dis* **26**, 577-589. → [Journal](#) | [PubMed](#)

*JIF*²⁰⁰⁷: **4.377**

NCBI GeneBank: [AM177178](#), [AM177179](#), [AM177180](#), [AM180763](#), [AM180764](#), [AM180765](#), [AM231689](#)

NCBI dbSNP: [ss52050753](#), [ss52085996](#), [ss65640445](#)

44. Leonidas DD, Swamy BM, Hatzopoulos GN, Gonchigar SJ, Chachadi VB, Inamdar SR, **Zographos SE** & Oikonomakos NG (2007) "Structural basis for the carbohydrate recognition of the Sclerotium rolfii lectin" *J Mol Biol* **368**, 1145-1161. → [Journal](#) | [PubMed](#)

*JIF*²⁰⁰⁷: **4.472**

PDBs: [2OFC](#), [2OFD](#), [2OFE](#)

45. Oikonomakos NG, Tiraidis C, Leonidas DD, **Zographos SE**, Kristiansen M, Jessen CU, Nørskov-Lauritsen L & Agius L (2006) "Iminosugars as potential inhibitors of glycogenolysis: Structural insights into the molecular basis of glycogen phosphorylase inhibition" *J Med Chem* **49**, 5687-5701. → [Journal](#) | [PubMed](#)

*JIF*²⁰⁰⁶: **5.115**


PDBs: [2G9Q](#), [2G9V](#), [2G9R](#), [2G9U](#)

46. Leonidas DD, Maiti TK, Samanta A, Dasgupta S, Pathak T, **Zographos SE** & Oikonomakos NG (2006) "The binding of 3'-N-piperidine-4-carboxyl-3'-deoxy-ara-uridine to ribonuclease A in the crystal" *Bioorgan Med Chem* **14**, 6055-6064. → [Journal](#) | [PubMed](#)

*JIF*²⁰⁰⁶: **2.624**

PDBs: [2G8Q](#), [2G8R](#)

47. Anagnostou E, Kosmopoulou MN, Chrysina ED, Leonidas DD, Hadjiloi T, Tiraidis C, **Zographos SE**, Gyorgydeak Z, Somsak L, Docsa T, Gergely P, Kollis FN & Oikonomakos NG (2006) "Crystallographic studies on two bioisosteric analogues, N-acetyl-beta-D-glucopyranosylamine and N-trifluoroacetyl-beta-D-glucopyranosylamine, potent inhibitors of muscle glycogen phosphorylase" *Bioorgan Med Chem* **14**, 181-189. → [Journal](#) | [PubMed](#)

Cover StoryJIF²⁰⁰⁶: **2.624**PDBs: [1WW2](#), [1WW3](#)

48. Watson KA, Chrysina ED, Tsitsanou KE, **Zographos SE**, Archontis G, Fleet GWJ & Oikonomakos NG (2005) "Kinetic and crystallographic studies of glucopyranose spirohydantoin and glucopyranosylamine analogs inhibitors of glycogen phosphorylase" *Proteins* **61**, 966-983.
→ [Journal](#) | [PubMed](#)

JIF²⁰⁰⁵: **4.684**PDBs: [1FS4](#), [1FTQ](#), [1FTW](#), [1FTY](#), [1FU4](#), [1FU7](#), [1FU8](#)

49. Archontis G, Watson KA, Xie Q, Andreou G, Chrysina ED, **Zographos SE**, Oikonomakos NG & Karplus M (2005) "Glycogen phosphorylase inhibitors: A free energy perturbation analysis of glucopyranose spirohydantoin analogues" *Proteins* **61**, 984-998. → [Journal](#) | [PubMed](#)
JIF²⁰⁰⁵: **4.684**

50. Santama N, Ogg SC, Malekkou A, **Zographos SE**, Weis K & Lamond AI (2005) "Characterization of hCINAP, a novel coilin-interacting protein encoded by a transcript from the transcription factor TAFIIID(32) locus" *J Biol Chem* **280**, 36429-36441. → [Journal](#) | [PubMed](#)

JIF²⁰⁰⁵: **5.854**NCBI GeneBank: [AJ878880](#), [AJ878881](#)

51. Chrysina ED, Oikonomakos NG, **Zographos SE**, Kosmopoulou MN, Bischler N, Leonidas DD, Kovacs L, Docsa T, Gergely P & Somsak L (2003) "Crystallographic studies on alpha- and beta-D-glucopyranosyl formamide analogues, inhibitors of glycogen phosphorylase" *Biocatal Biotransfor* **21**, 233-242. → [Journal](#)

JIF²⁰⁰³: **1.085**PDBs: [1P4G](#), [1P4H](#), [1P4J](#)

52. Oikonomakos NG, **Zographos SE**, Skamnaki VT & Archontis G (2002) "The 1.76 angstrom resolution crystal structure of glycogen phosphorylase B complexed with glucose, and

CP320626, a potential antidiabetic drug" *Bioorgan Med Chem* **10**, 1313-1319. → [Journal](#) | [PubMed](#)

*JIF*²⁰⁰²: **2.043**

PDB: [1H5U](#)

53. Oikonomakos NG, Kosmopoulou M, **Zographos SE**, Leonidas DD, Chrysina ED, Somsak U, Nagy V, Praly JP, Docsa T, Toth A & Gergely P (2002) "Binding of N-acetyl-N'-beta-D-glucopyranosyl urea and N-benzoyl-N'-beta-D-glucopyranosyl urea to glycogen phosphorylase b-Kinetic and crystallographic studies" *Eur J Biochem* **269**, 1684-1696. → [Journal](#) | [PubMed](#)

Cover Story



*JIF*²⁰⁰²: **2.999**

PDBs: [1K06](#), [1K08](#), [1KTI](#)

54. Oikonomakos NG, Schnier JB, **Zographos SE**, Skamnaki VT, Tsitsanou KE & Johnson LN (2000) "Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site" *J Biol Chem* **275**, 34566-34573. → [Journal](#) | [PubMed](#)

*JIF*²⁰⁰⁰: **7.368**

PDBs: [1C8K](#), [1E1Y](#), [1GFZ](#)

55. Oikonomakos NG, Tsitsanou KE, **Zographos SE**, Skamnaki VT, Goldmann S & Bischoff H (1999). Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate. *Protein Science* **8**, 1930-1945. → [Journal](#) | [PubMed](#)

*JIF*¹⁹⁹⁹: **4.457**

PDBs: [2GPA](#), [3AMV](#)

56. Tsitsanou KE, Oikonomakos NG, **Zographos SE**, Skamnaki VT, Gregoriou M, Watson KA, Johnson LN & Fleet GWJ (1999). Effects of commonly used cryoprotectants on glycogen phosphorylase activity and structure. *Protein Science* **8**, 741-749. → [Journal](#) | [PubMed](#)

Cover Story



*JIF*¹⁹⁹⁹: **4.457**

PDBs: [1B4D](#), [1BX3](#)

57. Heightman TD, Vasella A, Tsitsanou KE, **Zographos SE**, Skamnaki VT & Oikonomakos NG (1998). Cooperative interactions of the catalytic nucleophile and the catalytic acid in the inhibition of beta-glycosidases. Calculations and their validation by comparative kinetic and structural studies of the inhibition of glycogen phosphorylase b. *Helvetica Chimica Acta* **81**, 853-864. → [Journal](#)

JIF¹⁹⁹⁸: **2.463**PDB: [1AXR](#)

58. Krulle T, delaFuente C, Pickering L, Aplin RT, Tsitsanou KE, **Zographos SE**, Oikonomakos NG, Nash RJ, Griffiths RC & Fleet GWJ (1997). Triazole carboxylic acids as anionic sugar mimics? Inhibition of glycogen phosphorylase by a D-glucotriazole carboxylate. *Tetrahedron-Asymmetry* **8**, 3807-3820. → [Journal](#)

JIF¹⁹⁹⁷: **2.499**

59. **Zographos SE**, Oikonomakos NG, Tsitsanou KE, Leonidas DD, Chrysina ED, Skamnaki VT, Bischoff H, Goldmann S, Watson KA & Johnson LN (1997). The structure of glycogen phosphorylase b with an alkyl-dihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor. *Structure* **5**, 1413-1425. → [Journal](#) | [PubMed](#)

JIF¹⁹⁹⁷: **7.633**PDB: [2AMV](#)

60. delaFuente C, Krulle TM, Watson KA, Gregoriou M, Johnson LN, Tsitsanou KE, **Zographos SE**, Oikonomakos NG & Fleet GWJ (1997). Glucopyranose spirohydantoins: Specific inhibitors of glycogen phosphorylase. *Synlett* **5**, 485-487. → [Journal](#)

JIF¹⁹⁹⁷: **2.646**

61. Krulle TM, delaFuente C, Watson KA, Gregoriou M, Johnson LN, Tsitsanou KE, **Zographos SE**, Oikonomakos NG & Fleet GWJ (1997). Stereospecific synthesis of spirohydantoins of β -glucopyranose: Inhibitors of glycogen phosphorylase. *Synlett*, 211-213. → [Journal](#)

JIF¹⁹⁹⁷: **2.646**

62. Oikonomakos NG, **Zographos SE**, Tsitsanou KE, Johnson LN & Acharya KR (1996). Activator anion binding site in pyridoxal phosphorylase b: The binding of phosphite, phosphate, and fluorophosphate in the crystal. *Protein Science* **5**, 2416-2428. → [Journal](#) | [PubMed](#)

JIF¹⁹⁹⁶: **4.867**PDBs: [2SKC](#), [2SKD](#), [2SKE](#)

63. Brandstetter TW, delaFuente C, Kim YH, Johnson LN, Crook S, Lilley P, Watkin DJ, Tsitsanou KE, **Zographos SE**, Chrysina ED, Oikonomakos NG & Fleet GWJ (1996). Glucofuranose analogues of hydantocidin. *Tetrahedron* **52**, 10721-10736. → [Journal](#)

JIF¹⁹⁹⁶: **2.232**

64. Brandstetter TW, Wormald MR, Dwek RA, Butters TD, Platt FM, Tsitsanou KE, **Zographos SE**, Oikonomakos NG & Fleet GWJ (1996). A galactopyranose analogue of hydantocidin. *Tetrahedron-Asymmetry* **7**, 157-170. → [Journal](#)

JIF¹⁹⁹⁶: **2.382**

65. Oikonomakos NG, **Zographos SE**, Johnson LN, Papageorgiou AC & Acharya KR (1995). The binding of 2-deoxy-glucose-6-phosphate to glycogen phosphorylase *b*: kinetic and crystallographic studies. *Journal of Molecular Biology* **254**, 900-917. → [Journal](#) | [PubMed](#)

JIF¹⁹⁹⁵: **5.346**PDB: [2PRI](#)

66. Oikonomakos NG, Kontou M, **Zographos SE**, Watson KA, Johnson LN, Bichard CJF, Fleet GWJ & Acharya KR (1995). N-acetyl- β -D-glucopyranosylamine: a potent T state inhibitor of glycogen phosphorylase. A comparison with α -D-glucose. *Protein Science* **4**, 2469-2477. → [Journal](#) | [PubMed](#)

JIF¹⁹⁹⁵: **4.806**PDB: [2PRJ](#)

67. Krulle TM, Watson KA, Gregoriou M, Johnson LN, Crook S, Watkin DJ, Griffiths RC, Nash RJ, Tsitsanou KE, **Zographos SE**, Oikonomakos NG & Fleet GWJ (1995). Specific inhibition of glycogen phosphorylase by a spirodiketopiperazine at the anomeric position of glucopyranose. *Tetrahedron Letters* **36**, 8291-8294. → [Journal](#)

JIF¹⁹⁹⁵: **2.257**

68. **Zographos SE**, Oikonomakos NG, Dixon HBF, Griffin WG, Johnson LN & Leonidas DD (1995). Sulphate-activated phosphorylase *b*: the pH-dependence of catalytic activity. *Biochemical Journal* **310**, 565-570. → [Journal](#) | [PubMed](#)

JIF¹⁹⁹⁵: **4.159**

69. Watson KA, Mitchell EP, Johnson LN, Cruciani G, Son JC, Bichard CJF, Fleet GWJ, Oikonomakos NG, Kontou M & **Zographos SE** (1995). Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection. *Acta Crystallographica D* **51**, 458-472. → [Journal](#) | [PubMed](#)

JIF¹⁹⁹⁵: **4.029**

70. Bichard CJF, Mitchell EP, Wormald MR, Watson KA, Johnson LN, **Zographos SE**, Koutra DD, Oikonomakos NG & Fleet GWJ (1995). Potent inhibition of glycogen phosphorylase by a spirohydantoin of glucopyranose: first pyranose analogues of hydantocidin. *Tetrahedron Letters* **36**, 2145-2148. → [Journal](#)

JIF¹⁹⁹⁵: **2.257**

71. Oikonomakos NG, Kontou M, **Zographos SE**, Tsitoura HS, Johnson LN, Watson KA, Mitchell EP, Fleet GWJ, Son JC, Bichard CJF, Leonidas DD & Acharya KR (1994). The design of potential antidiabetic drugs: Experimental investigation of a number of β -D-glucose analogue inhibitors of glycogen phosphorylase. *Eur J Drug Metab Pharmacokinet* **19**, 185-192. → [Journal](#) | [PubMed](#)

JIF¹⁹⁹⁴: **0.489**

1. **Zographos, SE***, Eliopoulos, E, Thireou T and Tsitsanou, KE (2018). OBP-structure-aided repellent discovery: An emerging tool towards the prevention of mosquito-borne diseases in CRC book series QSAR in Environmental and Health Sciences "**Computational design of chemicals for the control of mosquitoes and their diseases**", Edited by James Devillers, Chapter 3, pp. 65-105. **ISBN: 978-1498-7418-04** → [Publisher](#)
2. Somsak L, Czifrak K, Toth M, Bokor E, Chrysina ED, Alexacou KM, Hayes JM, Tiraidis C, Lazoura E, Leonidas DD, **Zographos SE** & Oikonomakos NG (2008). New inhibitors of glycogen phosphorylase as potential antidiabetic agents (**Review**). **Current Medicinal Chemistry** **15**, 2933-2983. → [Journal](#) | [PubMed](#)

*JIF*²⁰⁰⁸: **4.823**

3. N.G. Oikonomakos, E.D. Chrysina, C. Tiraidis, D.D. Leonidas, **S.E. Zographos** (2007). Conformation flexibility of the 280s peptide loop in glycogen phosphorylase: implications for inhibitor design. In **5th Hellenic Forum on Bioactive Peptides** (Cordopatis, P., Manessi-Zoupa, E.; Pairas, G. N.; eds.), Typorama, Patras, Vol.5, pp. 283-289. **ISBN: 960-7620-32-1**. → [PDF](#)
4. N.G. Oikonomakos, M. N. Kosmopoulou, D. D. Leonidas, E. D. Chrysina, C. Tiraidis, N. Bischler, K. E. Tsitsanou, **S. E. Zographos**, I. D. Kostas, and G. Eisenbrand (2006). Indirubin and indigo analogues as potential inhibitors of glycogenolysis: structural basis of glycogen phosphorylase inhibition. In **Indirubin, the red shade of indigo** (Meijer L., Guyard N., Skaltsounis L. & Eisenbrand G., eds) Editions "Life in Progress", Station Biologique, Roscoff, Chapter 18, pp. 177-189. **ISBN: 2-9518029-0-0**. → [PDF](#)
5. Tsitsanou, K.E., **Zographos, S.E.**, Skamnaki, V.T. & Oikonomakos, N.G. (1999). Molecular recognition in glycogen phosphorylase inhibitor design (**Review**). **Review of Clinical Pharmacology and Pharmacokinetics**, International edition, Pharmakon Press 13, 9-25. → [PDF](#)
6. Mitchell, E.P., Watson, K.A., Bichard, C.J.F., Fleet, G.W.J., **Zographos, S.E.**, Oikonomakos, N.G., Board, M. & Johnson, L.N. (1995). Concepts, difficulties and progress in structure based drug design. In **Making the Most of your Model** (Proceedings of the CCP4 Study Weekend, 6-7 January 1995 (Complied by Hunter, W.N., Thornton, J.M. & Bailey, S.), CCL Daresbury Laboratory, pp. 111-119. → [PDF](#)
7. Oikonomakos, N.G., Kontou, M., **Zographos, S.E.**, Koutra, D.D., Johnson, L.N., Watson, K.A., Mitchell, E.P., Fleet, G.W.J., Son, J.C. & Bichard, C.J.F. (1994). The design of potential antidiabetic drugs: β -D-glucose analogue inhibitors of glycogen phosphorylase (**Review**). **Review of Clinical Pharmacology and Pharmacokinetics**, Greek edition, Pharmakon Press **12**, 103-122. → [PDF](#)

Patents

Mosquito repellent composition comprising yarrow essential Oil. (2022)

Hellenic Industrial Property Organization (OBI), Application Number 20220100673/10.08.2022.

→ [GR20220100673A](#)

European Patent Office (EPO), Application Number EP22193561.2/01.09.2022.

→ [EP4321023A1](#)

Short communications

1. Iatrou K, Kythreoti G, Thireou T, Papachristos DP, Michaelakis A, Zographos SE, Thanu VC, Ranganathan S, Schulz S (2025). Natural Volatiles for Inhibition of Mosquito Biting Behaviors: An Integrated Screening Platform for Accelerated Discovery of ORco Co-Receptor Antagonists. *J Pharmacol. Exp. Ther.* 392, Issue 3, Suppl. 2025, 100670. → [Journal](#)
JIF²⁰²⁴: 3.8
2. Iatrou, K., Thireou, T., Kythreoti, G., Liggri, P.G.V., Michaelakis, A., Papachristos, D., Tsitsanou, K.E., **Zographos, S.E.**, Schulz, S. (2024). Natural anosmia-inducing compounds for control of mosquito biting behaviors: Machine learning-assisted determination of structural determinants for ORco ligands antagonizing odorant receptor function. Annual meeting of the American Society for Biochemistry and Molecular Biology (Discover BMB 2024), March 23–26, San Antonio, USA. *J Biol. Chem.* 300, Issue 3, Suppl. 9, S168. → [Journal](#)
JIF²⁰²⁴: 4.0
3. Iatrou, K., Kythreoti, G., Thireou, T., Karoussiotis, C., Georgoussi, Z., **Zographos, S.E.**, Liggri, P.G.V., Michaelakis, A., Schulz, S. (2022) Novel Anosmia-Inducing Compounds for Environmentally Friendly Mosquito Vector Control: Structural Determinants of ORco Ligands Antagonizing Odorant Receptor Function. Experimental Biology Annual Meeting (EB 2022), 2-5 April 2022, Philadelphia, PA, USA. *FASEB J.* 36, Suppl. 1. DOI: 10.1096/fasebj.2022.36.S1.R4433 → [Journal](#)
JIF²⁰²²: 4.8
4. Liggri, P.G.V., Tsitsanou, K.E., Spyros E. **Zographos, S.E.***(2019). Structural and biochemical studies of an Odorant Binding Protein from the malaria vector *Anopheles gambiae*. The 44th FEBS congress, 6-11 July 2019, Krakow, Poland. *FEBS Open Bio*, 9: P-27-070. DOI: 10.1002/2211-5463.12675 → [Journal](#)
JIF²⁰¹⁹: 2.141
5. Tsitsanou, K.E., Drakou, C.E. & **Zographos, S.E.** (2013). The 3D domain-swapped dimer of the "Plus-C" odorant binding protein 48 from *Anopheles gambiae*. *MAX-lab Activity Report 2013* → [Report Online](#)
6. Katerina E. Tsitsanou, Demetres D. Leonidas, Spyros E. Zographos (2012) Chrysin inhibits glycogen phosphorylase by binding at the inhibitor site. *MAX-lab Activity Report 2012* → [Report Online](#)
7. Katerina E. Tsitsanou, Christina E. Drakou, Demetres D. Leonidas, Spyros E. Zographos (2012) Mosquito Odorant Binding Protein 1 as a target for the structure-based discovery of novel host-seeking disruptors. *MAX-lab Activity Report 2012* → [Report Online](#)
8. Katerina E. Tsitsanou, Christina E. Drakou, Maria Keramioti and **Spyros E. Zographos** (2010). Crystal structure of odorant binding protein 4 from *Anopheles gambiae* complexed with *N*-Phenyl-1-1naphthylamine. *MAX-lab Activity Report 2010*, pp. 382-383. → [Report Online](#)
9. V.T. Skamnaki, A. Katsandi, S. Manta, E. Tsoukala, **S.E. Zographos**, M. Kontou, P. Zoumpoulakis, D. Komiotis and D.D. Leonidas (2010). The binding of 1-(β-D-glucopyranosyl) pyrimidine derivatives to Glycogen phosphorylase b. *MAX-lab Activity Report 2010*, pp. 374-375. → [Report Online](#)

10. Katerina E. Tsitsanou, Christina E. Drakou and **Spyros E. Zographos** (2009). The structure of odorant binding protein 4 from *Anopheles gambiae*. **MAX-lab Activity Report 2009**, pp. 374-375. → [Report Online](#)
PDBs: [8C6E](#), [8C6G](#), [8BXV](#)
11. **Zographos SE**, Leonidas DD, Alexacou KM, Gimisis T, Hayes JM, Oikonomakos NG, Wen X, Sun H, Liu J, Cheng K, Zhang P, Zhang L, Hao J & Ni P (2008). Pentacyclic triterpenes, inhibitors of glycogen phosphorylase, as potential drugs for type 2 diabetes: X-ray crystallographic studies. **Planta Medica 74**, 1146-1147. → [Journal](#)
JIF²⁰⁰⁸: 1.960
12. **Spyros E. Zographos**, Christina E. Drakou, Anna Malekkou, Niovi Santama, Joseph M. Hayes, Demetres D. Leonidas, Angus I. Lamond, A. Siafaka-kapadai and Nikos G. Oikonomakos (2008). Crystal Structure of the nuclear factor hCINAP in complex with ADP refined to 1.8 Å resolution: Insights into the function of hCINAP. **MAX-lab Activity Report 2008**, pp. 412-413. → [Report Online](#)
13. V.G. Tsirkone, K. Dossi, **S.E. Zographos**, C. Drakou, N.G. Oikonomakos, M. Kontou and D.D. Leonidas (2008). The binding of two 5' phosphate uridine analogues to Ribonuclease A: implications for structure based inhibitor design. **MAX-lab Activity Report 2008**, pp. 402-403.
14. Tiraidis, C., Alexacou, K.-M., **Zographos, S.E.**, Leonidas, D.D., Gimisis, T., Oikonomakos, N.G.(2007). FR258900, a potential anti-hyperglycaemic drug, isolated from Fungus No. 138354, binds at the allosteric site of glycogen phosphorylase. **EMBL, Hamburg Outstation, Annual Report 2007, Part II**, pp. 135-136. → [Report Online](#)
15. **S.E. Zographos**, D.D. Leonidas, E. Lazoura, K. Dossi, P.V. Konarev, A.G. Kikhney, D.I. Svergun, D. Schmoll, E. Defossa and N.G. Oikonomakos (2007). Experimental evidence for the existence of an intermediate form of glucokinase, which accounts for the sigmoidal kinetic behaviour of the enzyme. **EMBL, Hamburg Outstation, Annual Report 2007, Part II**, pp. 371-372. → [Report Online](#)
16. K. Dossi, D.D. Leonidas, J. Soucek, J. Matoucek, P. Poucková, **S.E. Zographos**, and N.G. Oikonomakos (2007). Structure assisted inhibitor design on bovine seminal ribonuclease: The binding of uridyl nucleotide inhibitor. **EMBL, Hamburg Outstation, Annual Report 2007, Part II**, pp. 219-220. → [Report Online](#)
17. E. Anastasi, **S.E. Zographos**, V. Skamnaki, D.D. Leonidas., R. Kardakari., P.V. Konarev, D.I. Svergun, E. Defossa and N.G. Oikonomakos (2006). Small Angle X-ray Scattering of human glucokinase in complex with a potent activator. **EMBL, Hamburg Outstation, Annual Report 2006, Part II**, pp. 367-368. → [Report Online](#)
18. Oikonomakos, N.G., Tiraidis, C., Leonidas, D.D., **Zographos, S.E.**, Kristiansen, M., Jessen, C.U., Norskov-Lauritsen, L., Agius, L (2006). Iminosugars as potential inhibitors of glycogenolysis. **EMBL, Hamburg Outstation, Annual Report 2006, Part II**, pp. 125-126. → [Report Online](#)

19. Leonidas, D.D., Maiti, T.K., Samanta, A., Dasgupta, S., Pathak, T., **Zographos, S.E.**, Oikonomakos, N.G (2006). The binding of 3'-N-piperidine-4-carboxyl-3'-deoxy-ara uridine to Ribonuclease A in the crystal. **EMBL, Hamburg Outstation, Annual Report 2006, Part II**, pp. 227-228. → [Report Online](#)
20. Leonidas, D.D., Hatzopoulos, G.N., Matousek, J., **Zographos, S.E.**, Oikonomakos, N.G. (2005). The binding of IMP to bovine seminal ribonuclease. **EMBL, Hamburg Outstation, Annual Report 2005, Part II**, pp. 305-306. → [Report Online](#)
21. Oikonomakos, N.G., **Zographos, S.E.**, Skamnaki, V.T. & Archontis, G (2001). Structural comparison between the crystal structures of muscle glycogen phosphorylase b and liver glycogen phosphorylase a complexed with indole-2-carboxamide inhibitors, potential antidiabetic drugs. **EMBL, Hamburg Outstation, Annual Report 2001**, pp. 237-238. → [Report Online](#)
22. Oikonomakos, N.G., **Zographos, S.E.**, Skamnaki, V.T. & Tsitsanou, K.E. (2000). Structural studies on glycogen phosphorylase complexes with potent inhibitors of the enzyme: the binding of flavopiridol. Crystallographic studies of a very potent inhibitor of glycogen phosphorylase. **EMBL, Hamburg Outstation, Annual Report 2000**, pp. 197-198. → [Report Online](#)
23. Oikonomakos, N.G., Tsitsanou, K.E., Skamnaki, V.T. & **Zographos, S.E.** (1999). Glycogen phosphorylase: a molecular target for structure assisted drug design. **EMBL, Hamburg Outstation, Annual Report 1999**, pp. 114-115. → [Report Online](#)
24. **Zographos, S.E.**, Tsitsanou, K.E., Chrysina, D.E., Oikonomakos, N.G., Johnson, L.N., Goldmann, S. & Straub, A. (1996). Crystallographic studies of a very potent inhibitor of glycogen phosphorylase. **HASYLAB Annual Report Part II** (edited by H. Bartunik, W. Laasch & V. Lamzin), pp. 517-518.
25. **Zographos, S.E.**, Tsitsanou, K.E., Chrysina, E.D. & Oikonomakos, N.G. (1996). Inhibitor binding studies to T-state glycogen phosphorylase b. **SYNCHROTRON RADIATION DEPARTMENT, Daresbury Laboratory 1995-96, Scientific Reports Volume II**, pp. 743-744.
26. Watson, K.A., Gregoriou, M., Garman, E.F., Mitchell, E.P., Johnson, L.N., Bichard, C.J.F., Krulle, T.M., Taylor, H., Fleet, G.W.J., **Zographos, S.E.**, Kontou, M., Koutra, D.D. & Oikonomakos, N.G. (1996). X-ray structural studies of Escherichia coli maltodextrin phosphorylase (ECMP) and high resolution X-ray binding studies of glucose analogue inhibitors of glycogen phosphorylase (GP): Glucose analogue inhibitor studies. **SYNCHROTRON RADIATION DEPARTMENT, Daresbury Laboratory 1995-96, Scientific Reports Volume II**, pp. 733-734.
27. Oikonomakos, N.G., **Zographos, S.E.**, Kontou, M., Vatzaki, E.H., Tzartos, S.J., Koutsagelou, G., Acharya, K.R., Papageorgiou, A.C. & Johnson, L.N. (1994). X-ray crystallographic analysis of (i) pyridoxal reconstituted R-state phosphorylase b and (ii) Fab fragments of pathogenic monoclonal antibodies against the nicotinic acetylcholine receptor. **SYNCHROTRON RADIATION, Appendix to the Daresbury Annual Report 1993/1994**, p. 61.

28. Kontou, M., Oikonomakos, N.G., **Zographos, S.E.**, Johnson, L.N., Watson, K.A., Mitchell, E.P., Fleet, G.W.J., Son, J.C. & Bichard, C.J.F. (1994). Design of glucose analogue inhibitors of glycogen phosphorylase (GP): A study with β -glucopyranosylamines. *Eur. J. Drug. Metab. Pharmacokinet.* **19**, SUPPL., 67.

Interviews

- Interview "Research on the development of plant repellents from the Greek flora" on the morning show of Ms. K. Houzouri, at the **radio station of the Church of Greece, 98.5 FM 30/6/2020**. → [Listen the interview \(in Greek\)](#)
- Newspaper article entitled "A daisy that can cut the wings of a...tiger" about research of QFytoTera consortium on insect repellents. *In newspaper "Kathimerini", Sunday edition, published on 28/6/2020, No. sheet 30.455, p.32* (Editor Ms. Ioanna Fotiadi). → [Digital edition \(in Greek\)](#)
- **Dr. Spyros E. Zographos** (EUROSTRUCT coordinator) (2012) "The new centre for structural Biology: The Structural Biology and Chemistry Group (SBCG) of the National Hellenic Research Foundation have overseen a project, EUROSTRUCT, which has dramatically transformed their capabilities by creating a centre of excellence in structural biology in Greece" in *Projects magazine, (Insight Publishers Ltd., UK, ed.). 27*, 54-55. → [Digital edition](#)
- Dr. Kostas Iatrou (ENAROMaTIC coordinator) and **Dr. Spyros E. Zographos** (ENAROMaTIC partner) (2011) "Greek plants in the fight against malaria" in *Pathfinder Eco-Science* → [View video \(in Greek\)](#)

Research Funding

Running funded projects

- **"iStink:** Insect-Inspired Biosensor for Water Quality Monitoring. Exploratory Interdisciplinary Projects of Early-Career Researchers, 1st NHRF Internal Call, Period 2025– 2026. NHRF code: 0867, Sub-Project 4. In collaboration with Theoretical and Physical Chemistry Institute (TPCI/NHRF). **(01/01/2025–31/12/2026). Budget: 25,000 €.**
Role: Host Laboratory/Academic supervisor

Completed funded projects

➤ *As coordinator and/or Scientific Responsible for ICB*

- **"3D-ORco:** Advanced Research on the 3D structure of Mosquito Odorant Receptor coreceptor". Hellenic Foundation for Research and Innovation (H.F.R.I.) under the "1st Call for H.F.R.I. Research Projects to support Faculty members and Researchers and the procurement of high-cost research equipment" (Project Number: HFRI-FM17-637) in collaboration with NCSR-Demokritos, Hellenic Pasteur Institute, University of Helsinki, Finland and University of Dublin, Ireland. **(28/2/2020-27/4/2024). Budget: 180.000 €.**
- **"QFytoTera:** Nanoemulsions of plant oils with moisturizing and insect repellent properties" under the Operational Programme "Research, Entrepreneurship and Innovation" EPAnEK-NSRF 2014-2020 (MIS 5030853) for collaborative R&D projects

between academic institutions and the private sector (in collaboration with Qualia Pharma Ltd., Benaki Phytopathological Institute and the University of Patras). **(9/7/2018-8/7/2022). Budget: 630,005.37 €**

- **"IKYMOS:** Mosquito Odorant Binding Proteins as molecular targets for the discovery of new effective repellents/attractants. "State Scholarships Foundation (IKY) Doctorate Scholarship 2016-2019 to Ms. P. Liggri" NSRF (ΕΣΠΑ) 2014-2020 **(8/12/2016-7/12/2019). Scholarship: 29.408,4 €.**
Role: Supervisor
- **"PREVENT:** Molecular, functional and structural analysis of Mosquito OBPs for Prevention of Vector-Borne Infectious Diseases" General Secretariat for Research and Technology, Research grant ESPA R&D project of bilateral cooperation Greece-Turkey 2013-2014 in collaboration with Ass. Prof. M. Senay Sengul, Department of Molecular Biology and Genetics, Gaziosmanpasa University, Tokat, Turkey **(20/12/2013-31/12/2015).** Coordinator Dr. S. E. Zographos, IBMCB/NHRF. **Budget: 30,000 €**
Role : Coordinator/ Scientific Responsible
- **"ENAROMaTIC:** European Network for Advanced Research on Olfaction for Malaria Transmitting Insect Control." FP7-HEALTH-2007-2.3.2-9 (GA-222927), **(1/12/2008-30/11/2012);** Coordinator Dr. K. Iatrou, NCR Demokritos. **Budget for SBC1: 280,000 €**
Role : Scientist in charge for ICB /WP5 leader
- **"EUROSTRUCT:** European consolidation and promotion of research capacity in the area of structure based drug discovery". FP7-REGPOT-2008-1, (GA-230146), **(1/2/2009-31/1/2012);** Coordinator Dr. S. E. Zographos, IBMCB/NHRF. **Budget: 970,300 €.**
Role: Coordinator. [Read About EUROTRUCT](#)
- **"Protein complexes of CINAP:** composite molecular targets for the understanding of human disease". Cyprus Research Promotion Foundation, Thematic Research Grant YGEIA, GA-0506/05 **(2007-2009).** Coordinator Prof. N. Santama, University of Cyprus. **Budget for PI: 16,879 €**
Role : Scientist in charge for ICB
- **"Structure-function relationship of TAF9 proteins"** Human Resources and Mobility activity, Marie Curie European Reintegration Grant, MERGE-CT-2004-006358, **(2004-2005).** **Budget: 40,000 €.**
Role : Coordinator
- **"Structure/function relationships of recombinant human TAFs9 proteins"** Greek General Secretariat for Research and Technology, Research Grant ENTER 2001, GA-01ER 115 **(2004-2006).** Coordinator Dr. N. Oikonomakos, NHRF. **Budget: 65,588 €.**
Role : Reintegrated Researcher/ Scientist in charge for ICB

➤ **As partner**

- **"INSPIRED:** The National Research Infrastructures on Integrated Structural Biology, Drug Screening Efforts and Drug target functional characterization" National Research Infrastructures NSRF (ΕΠAvEK) 2014-2020. Coordinator Dr. E. Chrysina **(3/9/2018-30/9/2022).** **Budget for SBC1: 76,000€ (Upgrade of Crystallization Infrastructure).** Role: **Partner/member of the steering committee**

- **"OMIC-ENGINE** Synthetic Biology: from omics technologies to genomic engineering" National Research Infrastructures NSRF (ΕΠAvEK) 2014-2020. Coordinator Prof. K. Mathiopoulos, University of Thessaly (Scientist in charge for ICB/NHRF Dr. G. Skretas), **(1/1/2018-30/6/2022) Budget for SBC1: 500€ (travels). Role: Partner**
- **"STHENOS-β:** Targeted therapeutic approaches against degenerative diseases, with emphasis on cancer and aging: Optimization of targeted bioactive compounds" Ministry of Education, Lifelong Learning, and Religious Affairs, "Development Proposals of Research Institutions - KRIPIS", NSRF 2014-2020. O.P. "Competitiveness & Entrepreneurship" and Regions in Transition" **(1/1/2017-30/06/2021);** Coordinator Dr. A. Pintzas (IBMCB Director), IBMCB/ NHRF. **Budget for SBC1: 46,800€ (Personnel and consumables).** Role: **Partner/WP1 leader**
- **"INSTRUCT-Ultra:** Releasing the full potential of Instruct (Integrating infrastructures for Structural Biology) to expand and consolidate infrastructure services for integrated structural life science research". H2020-INFRADEV-2016-1 (GA-731005) **(01/01/2017-31/12/2020).** Coordinator D. Stuart, University of Oxford (Scientist in charge for IBMCB/NHRF Dr. E. Chrysina), **Budget for SBC1: 750€ (travels).** Role: **Partner/Member of the general assembly.**
- **"IKYMOS-Pos:** A combined methodology for the discovery of compounds with insect repellency properties" IKY Fellowships of Excellence for Postgraduate Studies in Greece-Siemens Program to Dr. E. Kritsi. **(16/04/2017- 31/08/2017)** Scientific Responsible: P.Zoumpoulakis. **Budget: 13,500 €**
Role : Partner
- **'STHENOS:** Targeted therapeutic approaches against degenerative diseases, with emphasis on cancer and aging" Ministry of Education, Lifelong Learning, and Religious Affairs, "Development Proposals of Research Institutions - KRIPIS", NSRF 2007-2013. O.P. "Competitiveness & Entrepreneurship" and Regions in Transition" **(1/1/2013-31/12/2015);** Coordinator Dr. A. Pintzas (IBMCB Director), IBMCB/ NHRF. **Budget for SBC1: 120,000 €**
Role : Partner
- **"ARCADE:** Advancement of Research Capability for the Development of New Functional Compounds" FP7-REGPOT-2009-1, (GA-245866), **(01/12/2009-30/5/2013);** Coordinator Dr. B. Steele, IBMCB/NHRF. **Budget for SBC1: 205,000 €**
Role : Partner
- **"Crystallisation, co-crystallisation, and crystallographic studies with human pancreatic glucokinase, a molecular target for types 2 diabetes therapy"** by Aventis Pharma Deutschland GmbH, a company of the sanofi-aventis group, Frankfurt, Germany **(2005-2006).** Coordinator Dr. N. Oikonomakos, NHRF **Budget: 10,000 €.**
Role : Principal Investigator.
- **"Structure/function relationships of new human protein CIP1 with molecular pathogenesis of neurodegenerative disorders".** Cyprus Research Promotion Foundation, Research Grant PENEK 2004-2005, ENISX 0603/03 **(2004-2006).** Coordinator Prof. N. Santama, University of Cyprus. **Budget Total/for PI: 60,000/3,595 €.** Role: **Scientist in charge from 1.06.2004 to 31.8.200. From 01.09.2004 PI moved back to Greece and continued the project as Principal Investigator at NHRF.**

- **"Inhibitors of glycogen phosphorylase and phosphorylase kinase as potential antidiabetic drugs"** Greek General Secretariat for Research and Technology, Research grant ENTER 2004, GA-04ER 70 (**2006-2008**). Coordinator Dr. N. Oikonomakos (**passed away on 31.08.2008**), NHRF. **Budget: 78,000 €** (Business Partner **Pfizer Inc**, Pfizer Global Research & Development, Groton Laboratories, USA; Contribution **8,000 €**) **Role: Principal Investigator. Coordinator from 1.09.2008 to 31.10.2008.**
- **"DRUGDESI:** Drug design at the molecular level using approximate and exact computational methods" Marie Curie Host Fellowships for the Transfer of Knowledge, MTKD-CT-2006-042776 (**2007-2011**). Coordinator Dr. N. Oikonomakos, (Dr. E. Chrysina since 1.09.2008), NHRF. **Budget: 186,396.40 €.**
Role: Collaborator (Structural and kinetic studies).
- **"EURODESY:** A European Research Training Site for the Design and Synthesis of Novel Neuroprotective and Hypoglycaemic Agents through a Multi-disciplinary approach" Marie Curie Early Stage Training (EST), MEST-CT-020575 (**2006-2010**). Coordinator Dr. N. Oikonomakos (Dr. D. Leonidas and Dr. I. Kostas since 1.09.2008), NHRF. **Budget: 984,182 €.**
Role: Collaborator (Structural and kinetic studies of glycogen phosphorylase, co-organizer/tutor of the workshop entitled "Workshop on Structure Based Drug Discovery" in the frame of EURODESY, NHRF, 2-6 June 2008).
- **"EURORES:** European Researchers' Night in Greece" FP7-PEOPLE-NIGHT-2008, CN-22, (**2008**). Coordinator Dr. N. Oikonomakos, NHRF. **Budget: 50,000 €.**
Role: Member of the implementation team.
- **"A Training, Implementation and Discrimination (TID) centre** (Heraklion TID-Centre) of the EU project «BIOXHIT»". BIOXHIT stands for Biocrystallography (X) on a Highly Integrated Technology Platform for European Structural Genomics and is funded under the FP6 of the EC (LSHG-CT-2003-503420) (**2006-2008**). Coordinator for Heraklion TID-Centre: Dr. K. Petratos, Institute of Molecular Biology and Biotechnology, Crete. **Budget: 60,000 €.**
Role: Collaborator (co-organizer of the international workshop entitled "From Crystals to Structures: Crystallization, Diffraction Data Collection, Processing and Phasing" 23-25 June 2008, IMBB-FORTH, Crete, Greece).
- **"Discovery of small-molecule inhibitors of glycogen phosphorylase, as potential hypoglycaemic agents, guided by structure-based drug design and in silico virtual ligand screening"** Greek General Secretariat for Research and Technology (EPAN) Research Grant for Scientific and Technological cooperation between Greece and USA, Prof. Alexander D. MacKerell, Jr., Computer-Aided Drug Design Center, School of Pharmacy, Univ. of Maryland, Baltimore, MD, USA (USA 046) (**2004-2006**). Coordinator Dr. N. Oikonomakos, NHRF. **Budget: 60,000 €.**
Role: Collaborator (Structural and kinetic studies of glycogen phosphorylase).
- **"Kinesin Molecular Motors and Neurodegenerative Diseases:** The case of ALS (Amyotrophic Lateral Sclerosis)", TELETHON Foundation (Cyprus), Research Grant (**2004-2005**). Coordinator Prof. N. Santama, University of Cyprus. **Budget: 60,000 €.**
Role: Post doctoral fellow (2 months).
- **"Structure-based design of new potential hypoglycaemic drugs"** General Secretariat for Research and Technology, Research grant EPAN R&D project of bilateral cooperation Greece-Hungary in collaboration with Prof. László Somsák, Department of Organic Chemistry,

University of Debrecen, Hungary (**2003-2005**). Coordinator Dr. N. Oikonomakos, NHRF.
Budget: 11,740 €.

Role: Collaborator (Structural and kinetic studies of glycogen phosphorylase).

- **"Cellular functions of kinesin like proteins and their role in human diseases"**, FP5-Improving Human Research Potential, Marie Curie Research Training Networks, GA IHP-RTN-99-1 (**2000-2004**). A collaborative research programme with 6 participating laboratories. Coordinator for University of Cyprus Prof. N. Santama. **Budget: 260,000 €.** **Role: Post doctoral fellow** (36 months).
- **"Structure-function relationship of allosteric proteins of muscle cells: molecular recognition and rational design of potential drugs"**. PENED-1999 (**1999-2000**), Ministry of Development, General Secretariat of Research and Technology (EPET II). Coordinator Dr. N. Oikonomakos, NHRF
Role: Post doctoral fellow
- **"Crystallographic studies of glycogen phosphorylase-inhibitor complexes of pharmacological importance"**, Access to modern instrumentation for X-ray crystallography". Institute of Molecular Biotechnology, Centre for Design and Structure in Biology (CDSB), Jena, Germany, (**1999-2000**). Coordinator Dr. N. Oikonomakos, NHRF.
Role : Post doctoral fellow

Access to European Large Infrastructures

- **"Structural Insights into the Role of Insect Chemosensory Proteins (CSPs) in Baculovirus-Induced Manipulation of Host Behavior"** Instruct-ERIC Project ID: 38328 (**2025**). X-ray Diffraction and Bio-SAXS, Hamburg, EMBL Beamline P13 (VID: 70008). **Budget:** Shipment expenses **Role: Principal Investigator**
- **"OBP structure-based discovery of novel marine-, plant-derived and bio-inspired compounds with mosquito repellent activity"** Instruct-ERIC Project ID: 29876 (**2024**). From Sample to X-ray Diffraction, Hamburg, EMBL Beamline P13 (VID: 51770). **Budget:** Shipment expenses **Role: Principal Investigator**
- **"Expression of mosquito 7-transmembrane Odorant Receptor co-receptor (ORco) using a baculovirus system in insect and mammalian cell lines, for structure determination studies"** Instruct-ERIC Project ID: 26717 (**Sep 2023-Jul 2024**). Membrane protein expression/ purification screening at Membrane Protein Production Facility, MPL, Harwell, UK (VID: 45371). **Budget:** Shipment expenses **Role: Principal Investigator**
- **"human 20S proteasome complex with structural activators"** Project ID: 24389 (**2022**). iNEXT-DISCOVERY: Structural biology research infrastructures for translational research and discovery; H2020 project #871037, **Budget:** Travel, accommodation and shipment expenses. **Role : Principal Investigator**
- **"OBP structure-based discovery of novel marine-, plant-derived and bio-inspired compounds with mosquito repellent activity – PART II"** Project ID: 20368 (**2022**). iNEXT-DISCOVERY: Structural biology research infrastructures for translational research and discovery; H2020 project #871037, **Budget:** Travel, accommodation and shipment expenses.. **Role : Principal Investigator**

- **"OBP structure-based discovery of novel marine-, plant-derived and bio-inspired compounds with mosquito repellent activity"** Project ID: 13686 (**2020**). iNEXT-DISCOVERY: Structural biology research infrastructures for translational research and discovery; H2020 project #871037, **Budget:** Expenses for shipment of samples. **Role :** **Principal Investigator**
- **"OBP-based reverse chemical ecology for the discovery of novel host-seeking disruptors of insects"** Project IDs: 2660 (**2017**), 6690 (**2018**). iNEXT: Access for translational research to European NMR, EM and X-rays infrastructures; H2020 project #653706. **Budget:** Travel, accommodation and shipment expenses. **Role :** **Principal Investigator**
- **"Design of novel inhibitors of the oncogenic BRAFV600E protein kinase"** Project ID: 6668 (**2018**). iNEXT: Access for translational research to European NMR, EM and X-rays infrastructures; H2020 project #653706. **Budget:** Travel, accommodation and shipment expenses. **Role :** **Principal Investigator**
- **"Greek network of protein crystallographers 2018, 2020, 2021, 2022"**. Block Allocation Group (BAG) application for Access to EMBL synchrotron radiation facilities **2018-2022**; Project IDs: MX-619, MX-726, MX-840, MX-868. Coordinator: Dr E. Stratikos/Dr. P. Giastas. **Role:** **Principal Investigator**
- **"Greek network of protein crystallographers 2016"**. Block Allocation Group (BAG) application for Access to EMBL synchrotron radiation facilities **2016-2017**; Project ID: MX-345, MX-372. **Role :** **Coordinator/Principal Investigator**
- **"Greek network of protein crystallographers 2014"**. Block Allocation Group (BAG) application for Access to ALBA, Spain synchrotron radiation facilities **2015**; Project ID: **2014060919**. Coordinator: Dr S.E. Zographos. **Role :** **Coordinator/Principal Investigator**
- **"Greek network of protein crystallographers 2014"**. Block Allocation Group (BAG) application for Access to EU synchrotron radiation facilities in the frame of FP7 project "BioStruct-X" (GA-283570), **2014-2015**; Coordinator: Dr G. Kontopidis. **Budget:** Travel and accommodation expenses. **Role :** **Principal Investigator**
- **"Greek network of protein crystallographers 2013"**. Block Allocation Group (BAG) application for long-term Access to Max-lab, Sweden synchrotron radiation facilities **August 2013-July 2015**; Project ID: **20130015**. Coordinator: Dr S.E. Zographos. **Role :** **Coordinator/Principal Investigator**
- **"Greek network of protein crystallographers 2013"**. Block Allocation Group (BAG) application for Access to ALBA, Spain synchrotron radiation facilities **2014**; Project ID: **2013100608**. Coordinator: Dr S.E. Zographos. **Role :** **Coordinator/Principal Investigator**
- **"Greek network of protein crystallographers 2013"**. Block Allocation Group (BAG) Access to EU synchrotron radiation facilities in the frame of FP7 project "BioStruct-X" (GA-

283570), **2013-2014**; Coordinator: Dr G. Kontopidis. **Budget:** Travel and accommodation expenses.

Role : Principal Investigator

- **"Advanced research for Mosquito Repellents"**, (Project No: PC-215; **2012**). Access to Structural Proteomics Facility OPPF, Rutherford Appleton Laboratory, Harwell Research Complex, Oxford, UK under the FP7 Capacities Specific Programme Research Infrastructures, "P-CUBE" (Infrastructure for Protein Production Platforms), (GA-227764). **Budget:** Travel, accommodation and subsistent expenses for a two (2) week visit.

Role : Principal Investigator

- **"Structural Studies using synchrotron Radiation of The Hellenic Structural Biology Network" (2011)**. Block Allocation Group (BAG) application for long-term Access to Max-lab, Sweden synchrotron radiation facilities **July 2011-June 2013**; Project ID: **20110270**. Coordinator: Dr D.D. Leonidas.

Role : Principal Investigator

- **"Instruct-Ellas, National consortium"**. Block Allocation Group (BAG) application for Access to EU synchrotron radiation facilities in the frame of FP7 project "BioStruct-X" (GA-283570), (**2011-2012**). Coordinator: Dr E. Chrysina. **Budget:** Travel and accommodation expenses.

Role : Principal Investigator

- **"X-ray data collection at EU Synchrotron Radiation Sources"**. Access to EU synchrotron radiation facilities in the frame of FP6 Research Infrastructure Actions "Structuring the European Research Area", "ELISA" (European Light Sources Activities) **Budget:** Travel and accommodation expenses for visits to: **Synchrotron Radiation Source CCLRC Daresbury Laboratory, UK**, Project No: 44229, (**2005**); 46131 (**2006**); 48049 (**2007**); 50114 (**2007**), **MAX-lab, Lund, Sweden** Project No: PX-151-2007 (**2007**); SAXS-149, (**2007**); PX-178, (**2008**); PX-184, (**2009-2010**); Project No PX-123, (**2011-2012**), **EMBL Hamburg Outstation, Germany** Project No: PX-03-16 (**2003**); PX-05-181, (**2005**); SAXS-07-12/SAXS-07-13, (**2007**); SAXS-09-142/PX-09-29/PX-09-30 (**2009**); PX-10-57/PX-10-58/PX-10-60/PX-10-61 (**2010**); PX-10-80/PX-10-81, (**2011**); MX-3, (**2012**). **Role : Coordinator/Principal Investigator**